Five-year echocardiographic follow-up after TAVI: structural and functional changes of a balloon-expandable prosthetic aortic valve

Aims Scarce data are available on the long-term structural and functional changes of prosthetic valves after transcatheter aortic valve implantation (TAVI). The objective was to evaluate with echocardiography the long-term structural and functional changes of prosthetic valves after TAVI. Methods and results Structural valve deterioration (SVD) was defined as leaflet thickening ≥3mm, presence of calcification and abnormal leaflet motion. Five-year echocardiographic follow-up was available in 96 out of 318 patients who underwent TAVI with a balloon-expandable device between April 2008 and December 2011. At 1-year follow-up, no patient showed SVD. At 5-year follow-up, SVD were observed in 29 (30%) patients who showed also a significant reduction of aortic valve area (AVA) together with an increase of mean and peak aortic pressure gradients at the latest echocardiography evaluation. Moreover, rate of central aortic valve regurgitation ≥2 was higher in SVD patients as compared to those without SVD, while there was no difference in terms of paravalvular regurgitation. Despite SVD, one patient only reached the criteria for severe stenosis and no reintervention was needed at 5-year follow-up. Variables independently associated with SVD were female sex, small body surface area, use of a 23 mm valve, and small AVA at pre-discharge echocardiogram. Conclusion At 5-year follow-up, 30% of patients who underwent TAVI with a balloon-expandable valve showed initial SVD. However, SVD was not associated with severe stenosis in most of the patients and had no significant impact on and clinical outcome.

[1]  P. Serruys,et al.  Five-year haemodynamic outcomes of the first-generation SAPIEN balloon-expandable transcatheter heart valve. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[2]  J. Zamorano,et al.  Recommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging. , 2016, European heart journal cardiovascular Imaging.

[3]  P. Pibarot,et al.  Incidence, Timing, and Predictors of Valve Hemodynamic Deterioration After Transcatheter Aortic Valve Replacement: Multicenter Registry. , 2016, Journal of the American College of Cardiology.

[4]  Patricia A Pellikka,et al.  Bioprosthetic Valve Thrombosis Versus Structural Failure: Clinical and Echocardiographic Predictors. , 2015, Journal of the American College of Cardiology.

[5]  B. Griffin,et al.  Early Bioprosthetic Valve Failure: Mechanistic Insights via Correlation between Echocardiographic and Operative Findings. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[6]  M. Mack,et al.  5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial , 2015, The Lancet.

[7]  Philippe Pibarot,et al.  Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. , 2015, JACC. Cardiovascular imaging.

[8]  T. Bourguignon,et al.  Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. , 2015, The Annals of thoracic surgery.

[9]  Jeroen J. Bax,et al.  Effect of aortic regurgitation following transcatheter aortic valve implantation on outcomes. , 2015, The American journal of cardiology.

[10]  M. Mack,et al.  Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. , 2015, European heart journal.

[11]  B. Iung,et al.  Long-term outcome after transcatheter aortic valve implantation , 2015, Heart.

[12]  J. Serfaty,et al.  Early Structural Valve Deterioration of Mitroflow Aortic Bioprosthesis: Mode, Incidence, and Impact on Outcome in a Large Cohort of Patients , 2014, Circulation.

[13]  Thoralf M Sundt,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[14]  Thoralf M Sundt,et al.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[15]  Bart Meuris,et al.  Antimineralization treatment and patient-prosthesis mismatch are major determinants of the onset and incidence of structural valve degeneration in bioprosthetic heart valves. , 2014, The Journal of thoracic and cardiovascular surgery.

[16]  Susheel Kodali,et al.  Two-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement , 2013 .

[17]  Anson Cheung,et al.  5-year outcome after transcatheter aortic valve implantation. , 2013, Journal of the American College of Cardiology.

[18]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, Journal of the American College of Cardiology.

[19]  S. Pocock,et al.  Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. , 2010, The New England journal of medicine.

[20]  E. Tay,et al.  Transcatheter Aortic Valve Implantation: Durability of Clinical and Hemodynamic Outcomes Beyond 3 Years in a Large Patient Cohort , 2010, Circulation.

[21]  Susan Armstrong,et al.  Hancock II bioprosthesis for aortic valve replacement: the gold standard of bioprosthetic valves durability? , 2010, The Annals of thoracic surgery.

[22]  S. Rahimtoola,et al.  Choice of prosthetic heart valve in adults an update. , 2010, Journal of the American College of Cardiology.

[23]  Bart Meuris,et al.  Prosthesis-Patient Mismatch Predicts Structural Valve Degeneration in Bioprosthetic Heart Valves , 2010, Circulation.

[24]  R. Suri Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years , 2009 .

[25]  Guidelines for reporting mortality and morbidity after cardiac valve interventions. , 2008, The Journal of thoracic and cardiovascular surgery.

[26]  N. Smedira,et al.  Failure modes of the Carpentier-Edwards pericardial bioprosthesis in the aortic position. , 2006, The Journal of heart valve disease.

[27]  J E Okies,et al.  Age and valve size effect on the long-term durability of the Carpentier-Edwards aortic pericardial bioprosthesis. , 2001, The Annals of thoracic surgery.